Trial Profile
Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin; Haematopoietic stem cell therapy
- Indications Haematological disorders
- Focus Therapeutic Use
- 12 Nov 2015 New trial record